DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for panhypopituitarism — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePanhypopituitarism maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for panhypopituitarism is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 27-year-old woman with panhypopituitarism from a suprasellar germinoma, including diabetes insipidus, hypothyroidism, adrenal cortex dysfunction, and hypogonadotropic ovarian failure, conceived and delivered healthy twins after treatment with thyroxin, cortisol, antidiuretic hormone, human menopausal gonadotropin, and human chorionic gonadotropin. This is a single case report from 2003; no control group exists, and the outcome cannot be generalised.
A novel homozygous HESX1 mutation (R160H) was identified in an 8-month-old child with panhypopituitarism. Neuroimaging showed anterior pituitary aplasia, a normal posterior pituitary, and a thin pituitary stalk, but no midline defects or optic nerve anomalies. The parents carried the mutation heterozygously, suggesting autosomal recessive inheritance. This 2011 report describes one patient; no treatment or outcome data beyond the genetic finding are provided.
A 2017 case describes a prepubertal woman with a homozygous PROP1 mutation (c.150delA) diagnosed in young adulthood. She had central hypopituitarism, hypogonadism, and growth hormone deficiency. With cautiously combined growth hormone therapy and sex hormone therapy, she achieved height exceeding family-based predictions and sexual maturation including regular menstrual cycles. This is a single case; no comparator group exists.
What remains missing are prospective trials with adequate sample sizes, standardised hormone replacement protocols, and long-term follow-up on cardiovascular, bone, and neurocognitive outcomes in panhypopituitarism. No randomised evidence guides the timing or dosing of growth hormone and sex hormone therapy in adult-diagnosed patients, and genetic screening strategies for HESX1 and PROP1 mutations have not been tested in unselected panhypopituitarism populations.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Obstetrics and Gynecology · 2003 · 15 citations
Successful twin pregnancy in panhypopituitarism caused by suprasellar germinoma
AbstractBACKGROUND: Pregnancy in a woman with hypopituitarism from a suprasellar germinoma is rare. CASE: A 27-year-old woman presented with panhypopituitarism from a suprasellar germinoma. She had diabetes insipidus, hypothyroidism, adrenal cortex dysfunction, and hypogonadotropic ovarian failure. When treated with thyroxin, cortisol, antidiuretic hormone, human menopausal gonadotropin, and human chorionic gonadotropin, she conceived and gave birth to healthy twins. CONCLUSION: Hormonal replacement therapy and ovulation induction resulted in a successful pregnancy in a woman with panhypopituitarism.
Journal of Pediatric Endocrinology and Metabolism · 2011 · 11 citations
A novel homozygous HESX1 mutation causes panhypopituitarism without midline defects and optic nerve anomalies
AbstractOBJECTIVE: There are many genes reported to have been associated with combined pituitary hormone deficiencies, but mutations in HESX1 strongly correlate with septo-optic dysplasia. Our aim was to determine the cause of panhypopituitarism in our patient. PATIENTS AND METHODS: We studied an 8-month-old child having panhypopituitarism. The coding exons of PIT1, PROP1, LHX3, and HESX1 genes were amplified. Direct sequencing was done after denaturing HLPC. RESULTS: We identified a novel homozygous mutation (R160H) within the homeodomain of HESX1, which, to our knowledge, is the first to be described in humans. Neuroimaging studies revealed anterior pituitary aplasia, a normal posterior pituitary gland, and a thin pituitary stalk but no midline abnormalities. Optic nerve studies showed no pathology. This mutation is also carried in the parents of the affected child in a heterozygous pattern, suggesting an autosomal recessive inheritance. CONCLUSION: These data demonstrate that homozygous HESX1 mutation causing an R160H substitution can result in panhypopituitarism without midline defects.
Frontiers in Endocrinology · 2017 · 1 citations · open access
Therapy-Induced Growth and Sexual Maturation in a Developmentally Infantile Adult Patient with a PROP1 Mutation
AbstractBACKGROUND: Hypopituitarism as a result of PROP1 (prophet of PIT1) mutation represents the most common genetic cause of combined deficiency of pituitary hormones and due to growth retardation it is typically diagnosed in childhood. CASE DESCRIPTION: We present a unique case report of a prepubertal woman with growth retardation in whom combined pituitary hormone deficiency [central hypopituitarism, hypogonadism, and growth hormone (GH) deficiency] caused by homozygous mutation c.150delA in the PROP1 gene was diagnosed late in young adulthood due to unfavorable life circumstances. Through cautiously combined GH therapy and sex hormone therapy, she has achieved better than expected height (exceeding predictions based on family height) and sexual maturation, including regular menstrual cycles. CONCLUSION: Early diagnosis of panhypopituitarism due to PROP1 mutation is essential for successful treatment; however, our case report shows that carefully titrated GH treatment and sex hormone substitution, although initiated in adulthood, enable restoration of physiological growth and sexual development in a hormonally infantile adult woman with a PROP1 mutation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
